← Eichor
Condition: Ventilator Associated Bacterial Pneumonia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Ventilator Associated Bacterial Pneumonia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT06841731Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia
Phase 3 · 1 location(s) · University Hospital, Toulouse · NCT03581370A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacte
Phase N/A · 12 location(s) · Innoviva Specialty Therapeutics · NCT06746883A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex
Phase 2 · 6 location(s) · Omnix Medical Ltd · NCT06087536Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients
Phase N/A · 1 location(s) · Centre Hospitalier de Saint-Denis · NCT07052604A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07327619Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients W
Phase 3 · 1 location(s) · BioVersys SAS · NCT07326540NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT05017766A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infecti
Phase 1 · 4 location(s) · Innoviva Specialty Therapeutics · NCT06801223Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infecti
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07089186Optimising TREATment for Severe Gram-Negative Bacterial Infections
Phase 4 · 41 location(s) · National University of Singapore · NCT07004049
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.